default author photo

Elisabeth Baudin

Epicentre (Paris)

SCHOLARLY PAPERS

2

DOWNLOADS

281

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Bedaquiline, Delamanid, Linezolid and Clofazimine for the Treatment of Rifampicin- and Fluoroquinolone-Resistant Tuberculosis (endTB-Q): A Phase 3, Open-Label, Multicentre, Randomised, Controlled, Stratified, Non-Inferiority Trial

Number of pages: 34 Posted: 06 Apr 2025
IRCSS Sacro Cuore Hospital, - Department of Infectious – Tropical Diseases and Microbiology, Interactive Research and Development Global, Singapore, University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis, Epicentre (Paris), Interactive Research and Development (IRD), Karachi, Pakistan, Interactive Research and Development (IRD), Karachi, Pakistan, Interactive Research and Development (IRD), Karachi, Pakistan, National Scientific Center of Phthisiopulmonology, University of Tübingen - Mycobacteriology Unit, Epicentre (Paris), National Scientific Center of Phthisiopulmonology, Médecins Sans Frontières (London), University of Montpellier - Translational Research in HIV and Infectious Diseases (TransVIHMI), Médecins Sans Frontières, Mumbai, India, Médecins Sans Frontières, Geneva, Switzerland, City Center of Phthisiopulmonology, Institute of Tropical Medicine - Mycobacteriology Unit, Hanoi Medical University - Vietnam National Lung Hospital, Médecins Sans Frontières, Geneva, Switzerland, Research Center Borstel, Partners In Health Lesotho, Médecins Sans Frontières, Harvard University - Department of Global Health and Social Medicine, University of Cape Town (UCT) - Division of Clinical Pharmacology, Socios En Salud Sucursal Peru, Institute of Tropical Medicine - Mycobacteriology Unit, The Indus Hospital and Health Network, University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis, Hanoi Lung Hospital, Hanoi Medical University - Vietnam National Tuberculosis Programme, Partners In Health Lesotho, University College London - MRC Clinical Trials Unit, Indian Council of Medical Research (ICMR), Indian Council of Medical Research (ICMR) - National AIDS Research Institute, Hanoi Lung Hospital, Pham Ngoc Thach Hospital, University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis, University of California, San Francisco (UCSF) - UCSF Center for Tuberculosis, Socios En Salud Sucursal Peru, University of Tübingen - Mycobacteriology Unit, The Indus Hospital and Health Network, Hospital Nacional Sergio E. Bernales, Harvard University - Division of Global Health Equity, Partners In Health Lesotho, Hospital Nacional Hipólito Unanue, Lima, Harvard University - Division of Global Health Equity, Médecins sans Frontières (Paris), Harvard University - Department of Global Health and Social Medicine and Independent
Downloads 190 (401,336)

Abstract:

Loading...

MDR-TB, pre-XDR-TB, multidrug-resistant tuberculosis, pre-extesively drug-resistant tuberculosis, BDLC, personalized medicine, precision medicine, clinical trial, extensive tuberculosis disease, limited tuberculosis disease

2.

Fexinidazole as a New Oral Treatment for Human African Trypanosomiasis Due to Trypanosoma Brucei Rhodesiense: A Prospective, Open-Label, Single-Arm, Phase 2-3, Benchmark Study

Number of pages: 26 Posted: 08 Oct 2024
Makerere University, Rumphi District Hospital, Lwala Hospital, Drugs for Neglected Diseases Initiative (DNDi), Drugs for Neglected Diseases Initiative (DNDi), Ministry of Health (Malawi), Republic of Uganda Ministry of Health, Institut de Recherche pour le Développement, University of Lisbon, University of Basel - Swiss Tropical and Public Health Institute, Drugs for Neglected Diseases Initiative (DNDi), Epicentre (Paris), Bruno Scherrer Conseil and Drugs for Neglected Diseases Initiative (DNDi)
Downloads 91 (742,061)

Abstract:

Loading...

fexinidazole, trypanosoma brucei rhodesiense, human African trypanosomiasis, clinical trial, Malawi, Uganda, efficacy, safety